US Q4 Consumer Health Earnings Preview: Inflation Impact Follows Pandemic-Driven Disruption
Executive Summary
Cost increases initially spurred by supply chain disruptions by COVID-19 pandemic have been noted by businesses across consumer product industries since soon after novel coronavirus spread accelerated in early 2020. More recently, OTC drug, nutritional supplement and personal care product providers began noting inflation’s influence on costs.
You may also be interested in...
Consumers’ Inflation Fatigue, Recession Fears May Put Health, Beauty Product Price Increases On Hold
Church & Dwight, Perrigo executives' comments at investor conferences could signal OTC drug, supplement and personal care product firms are moving from gauging pandemic impact on supply chains and consumer spending to anticipating shifts in consumer preferences and cost increases caused by inflation with recession appearing more likely every day.
J&J Full Steam Ahead On Separating Consumer Business While Inflation, Pandemic Slow Results
While target date for spinning out consumer business into publicly traded company remains some time in 2023, J&J includes additional details on separation timetable with its 2021 full-year and fourth-quarter results.
P&G Widens Pricing Strategy To At Least 60% Of Products As Costs Soar
Procter & Gamble’s pricing strategy now impacts 10 of its US product categories, with action also being taken broadly in non-US markets. President and CEO Jon Moeller calls this pricing "at a different level" historically speaking, and warns there will be ‘bumps in the road." But P&G is confident in its long track record and raises full-year guidance accordingly.